TORONTO, ON — December 15, 2025 — Leads & Copy — Medicenna Therapeutics Corp.’s President and CEO, Fahar Merchant, acquired 32,000 common shares of Medicenna at $1.11 per share on December 15, 2025, via the Toronto Stock Exchange, totaling $35,520.
Before the transaction, Dr. Merchant, along with Rosemina Merchant and Aries Biologics Inc., held 16,905,292 shares and 4,792,855 options, representing 20.27% of outstanding shares non-diluted and 24.60% partially diluted.
Following the transaction, their holdings increased to 16,937,292 shares and 4,792,855 options, accounting for 20.31% of outstanding shares non-diluted and 24.64% partially diluted.
Dr. Merchant relied on the normal course purchase exemption for the transaction, with an early warning report to be filed on SEDAR+ under Medicenna’s profile.
David Hyman, Chief Financial Officer of Medicenna, can be contacted at 416-648-5555 for a copy of the report.
Contact:
Fahar Merchant
416-648-5555
Source: Medicenna Therapeutics Corp.
